サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1714391

脂質調整剤市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、地域別、市場競合、2020-2030Fセグメント別

Lipid Regulators Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 180 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

脂質調整剤市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、地域別、市場競合、2020-2030Fセグメント別
出版日: 2025年04月25日
発行: TechSci Research
ページ情報: 英文 180 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

脂質調整剤の世界市場規模は2024年に72億1,000万米ドルで、2030年には98億4,000万米ドルに達し、予測期間中のCAGRは5.32%で成長すると予測されています。

同市場は、心血管疾患や糖尿病の世界の罹患率の上昇、人口の高齢化、コレステロール管理に対する意識の高まりなどを背景に着実な成長を遂げています。技術革新、特に神経や治療法の進歩、政府・民間セクターの投資拡大が、市場拡大の好条件を生み出しています。高齢者は慢性疾患にかかりやすくなっており、脂質異常症の管理や合併症の予防に不可欠な脂質調整剤の需要は増加すると予想され、予防的な心血管治療における重要性が高まっています。

市場概要
予測期間 2026-2030
市場規模：2024年 72億1,000万米ドル
市場規模：2030年 98億4,000万米ドル
CAGR：2025年～2030年 5.32%
急成長セグメント スタチン
最大市場 北米

市場促進要因

心血管疾患の有病率の上昇

主な市場課題

高い開発コスト

主要市場動向

バイオ医薬品の台頭

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の脂質調整剤市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別{スタチン（ブランドスタチン、スタチン配合剤、ジェネリックスタチン）、非スタチン（フィブリン酸誘導体、胆汁酸吸着剤、ニコチン酸誘導体、その他の新製品）}
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米の脂質調整剤市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の脂質調整剤市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋地域の脂質調整剤市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の脂質調整剤市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの脂質調整剤市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 合併と買収

第13章 世界の脂質調整剤市場：SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替治療法の脅威

第15章 競合情勢

  • AbbVie Inc
  • Amgen Inc.
  • Andrx Corp
  • AstraZeneca PLC
  • Bristol-Myers Squibb Co
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Dr. Reddy's Laboratories Ltd.

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 16259

The Global Lipid Regulators Market was valued at USD 7.21 billion in 2024 and is projected to reach USD 9.84 billion by 2030, growing at a CAGR of 5.32% during the forecast period. The market is experiencing steady growth driven by a rising global incidence of cardiovascular diseases and diabetes, an aging population, and increasing awareness of cholesterol management. Technological innovations, particularly in neural and therapeutic advancements, as well as increased government and private sector investments, are creating favorable conditions for market expansion. With the elderly being more vulnerable to chronic illnesses, the demand for lipid regulators-essential in managing dyslipidemia and preventing complications-is anticipated to increase, reinforcing their importance in preventive cardiovascular care.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.21 Billion
Market Size 2030USD 9.84 Billion
CAGR 2025-20305.32%
Fastest Growing SegmentStatins
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Cardiovascular Diseases

The global surge in cardiovascular diseases (CVDs) serves as a key catalyst for the lipid regulators market. CVDs, including coronary artery disease, stroke, and hypertension, are a leading cause of death globally. According to the World Health Organization, CVDs account for nearly 32% of all deaths worldwide. Dyslipidemia, characterized by abnormal cholesterol or triglyceride levels, is a primary risk factor in the development of CVDs. Lipid regulators, particularly statins and other lipid-lowering agents, are vital in controlling cholesterol levels, reducing disease progression, and improving patient outcomes. With a growing global focus on preventive healthcare, the demand for lipid-regulating therapies continues to rise, offering growth opportunities for pharmaceutical companies and healthcare providers.

Key Market Challenges

High Development Costs

High development costs remain a major challenge in the lipid regulators market. The process of discovering, developing, and commercializing new lipid-lowering drugs involves extensive R&D, clinical trials, and regulatory approvals, all of which require substantial financial investment. Preclinical and clinical research phases are time-consuming and expensive, involving the recruitment of skilled professionals and maintenance of specialized facilities. Additionally, ensuring safety and efficacy through compliance with stringent regulatory frameworks adds further financial burden. These cost-related barriers particularly affect smaller pharmaceutical firms, potentially limiting innovation and delaying market entry of newer lipid-regulating products.

Key Market Trends

Rise of Biopharmaceuticals

Biopharmaceuticals are reshaping the lipid regulators market by enabling more targeted, effective treatment options. Unlike traditional chemical-based drugs, biopharmaceuticals-such as monoclonal antibodies and recombinant proteins-interact with specific biological pathways to regulate lipid metabolism. These advanced therapies offer improved safety profiles and enhanced therapeutic outcomes, particularly for patients who are unresponsive to conventional statins. The advancement of technologies like gene editing and synthetic biology is accelerating the development of biologics. While the infrastructure and expertise required for biopharmaceutical development present initial investment challenges, the long-term benefits-such as premium pricing and extended patent exclusivity-make them a lucrative segment within the lipid regulators market.

Key Market Players

  • AbbVie Inc
  • Amgen Inc.
  • Andrx Corp
  • AstraZeneca PLC
  • Bristol-Myers Squibb Co
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Dr. Reddy's Laboratories Ltd.

Report Scope:

In this report, the Lipid Regulators Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lipid Regulators Market, By Type:

  • Statins (Branded statins, Statin combinations, and Generic statins)
  • Non-statins (Fibric-acid derivatives, Bile-acid Sequestrants, Nicotinic Acid Derivatives, and Other New Products)

Lipid Regulators Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • France
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Lipid Regulators Market.

Available Customizations:

Lipid Regulators Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lipid Regulators Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type {Statins (Branded statins, Statin combinations, and Generic statins), and Non-statins (Fibric-acid derivatives, Bile-acid Sequestrants, Nicotinic Acid Derivatives, and Other New Products)}
    • 5.2.2. By Region
    • 5.2.3. By Company (2024)
  • 5.3. Market Map

6. North America Lipid Regulators Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Lipid Regulators Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
    • 6.3.2. Canada Lipid Regulators Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
    • 6.3.3. Mexico Lipid Regulators Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type

7. Europe Lipid Regulators Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Lipid Regulators Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
    • 7.3.2. United Kingdom Lipid Regulators Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
    • 7.3.3. Italy Lipid Regulators Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type
    • 7.3.4. France Lipid Regulators Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
    • 7.3.5. Spain Lipid Regulators Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type

8. Asia-Pacific Lipid Regulators Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Lipid Regulators Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
    • 8.3.2. India Lipid Regulators Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
    • 8.3.3. Japan Lipid Regulators Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
    • 8.3.4. South Korea Lipid Regulators Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
    • 8.3.5. Australia Lipid Regulators Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type

9. South America Lipid Regulators Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Lipid Regulators Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
    • 9.3.2. Argentina Lipid Regulators Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
    • 9.3.3. Colombia Lipid Regulators Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type

10. Middle East and Africa Lipid Regulators Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Lipid Regulators Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
    • 10.3.2. Saudi Arabia Lipid Regulators Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
    • 10.3.3. UAE Lipid Regulators Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions

13. Global Lipid Regulators Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

  • 15.1. AbbVie Inc
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Amgen Inc.
  • 15.3. Andrx Corp
  • 15.4. AstraZeneca PLC
  • 15.5. Bristol-Myers Squibb Co
  • 15.6. Merck KGaA
  • 15.7. Novartis AG
  • 15.8. Pfizer Inc.
  • 15.9. Teva Pharmaceutical Industries Ltd
  • 15.10. Dr. Reddy's Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer